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ABSTRACT
Objectives Pancreatic cancer (PCa) is treatable by
surgery when detected at an early stage. Non-invasive
imaging methods able to detect both established
tumours and their precursor lesions are needed to select
patients for surgery. We investigated here whether
pancreatic preneoplasia could be detected prior to the
development of invasive cancers in genetically
engineered mouse models of PCa using metabolic
imaging.
Design The concentrations of alanine and lactate and
the activities of lactate dehydrogenase (LDH) and alanine
aminotransferase (ALT) were measured in extracts
prepared from the pancreas of animals at different
stages of disease progression; from pancreatitis, through
tissue with predominantly low-grade and then high-
grade pancreatic intraepithelial neoplasia and then
tumour. 13C magnetic resonance spectroscopic imaging
(13C-MRSI) was used to measure non-invasively changes
in 13C labelling of alanine and lactate with disease
progression, following injection of hyperpolarised [1-13C]
pyruvate.
Results Progressive decreases in the alanine/lactate
concentration ratio and ALT/LDH activity ratio with
disease progression were accompanied by a
corresponding decrease in the [1-13C]alanine/[1-13C]
lactate signal ratio observed in 13C-MRSI images of the
pancreas.
Conclusions Metabolic imaging with hyperpolarised
[1-13C]pyruvate enables detection and monitoring of the
progression of PCa precursor lesions. Translation of this
MRI technique to the clinic has the potential to improve
the management of patients at high risk of developing
PCa.
INTRODUCTION
Pancreatic cancer (PCa) is the fourth leading cause
of cancer-related deaths, with approximately equal
rates of annual incidence and mortality.1 The
5-year survival rate has remained at 5–6% for the
last four decades.2 3 At the time of diagnosis,
>80% of patients are ineligible for curative surgical
treatment, and of those amenable to surgery, the
majority will relapse.4 Late clinical presentation,
inaccurate early diagnosis using current biomarkers
and imaging methods, limited treatment options
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Signiﬁcance of this study
What is already known on this subject?
▸ Pancreatic cancer is one of the leading causes of
cancer-related deaths. If detected at an early
stage, it is potentially curable.
▸ New diagnostic techniques are urgently required
for the detection of early-stage pancreatic cancer.
▸ Application of dynamic nuclear polarisation has
increased the sensitivity of magnetic resonance
spectroscopy by more than 10 000-fold, allowing
real-time imaging of tissue metabolism in vivo.
▸ Hyperpolarised [1-13C]pyruvate has been used
recently in humans for the ﬁrst time to detect
tumours in the prostate.
What are the new ﬁndings?
▸ Progression of pancreatic cancer from tissue
containing predominantly low-grade precursor
lesions to tissue containing tumour showed a
decreasing alanine/lactate concentration ratio
and alanine aminotransferase (ALT)/lactate
dehydrogenase (LDH) activity ratio in tissue
extracts.
▸ 13C-magnetic resonance spectroscopic images of
the pancreas following injection of hyperpolarised
[1-13C]pyruvate showed a decrease in the [1-13C]
alanine/[1-13C]lactate signal ratio with disease
progression, which was explained by the changes
in alanine and lactate concentrations and LDH and
ALT activities.
▸ Metabolic imaging with hyperpolarised [1-13C]
pyruvate can be used to detect and monitor the
progression of pancreatic cancer precursor lesions
in a mouse model of the human disease.
How might it impact on clinical practice in
the foreseeable future?
▸ 13C-magnetic resonance spectroscopic imaging
with hyperpolarised [1-13C]pyruvate may allow
a non-invasive, radiation-free method for early
detection of disease progression in individuals
at high risk of developing pancreatic cancer,
allowing curative intervention to be offered at
an earlier stage and consequently improving
patient survival and prognosis.
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and drug resistance continue to make PCa difﬁcult to treat.5
Since PCa is potentially curable by surgery, the best option to
improve survival rates would be to increase the number of can-
didates for surgery through early detection of disease
progression.
Pancreatic ductal adenocarcinoma (PDA) evolves through a
spectrum of intraepithelial neoplasia (PanIN) precursor lesions
as a result of accumulating mutations. PanIN1 and PanIN2 can
occur in normal individuals and in chronic pancreatitis without
ever evolving into PDA, whereas PanIN3, termed carcinoma in
situ, shares many of the genetic alterations of PDA and has a
greater potential to evolve into invasive PDA.6–10 Between 10%
and 36% of those diagnosed with PCa have a genetic predispos-
ition, for example, individuals with familial pancreatic cancer
(FPC), and selective screening of this population is recom-
mended.11–13 However, identiﬁcation of curable precursor
lesions of PDA in these individuals is still unsatisfactory.
Non-invasive proton magnetic resonance spectroscopy
(1H-MRS) measurements of tissue metabolites have been limited
by low sensitivity and masking of the lactate proton signal by
intense overlapping lipid resonances, with the few studies that
have been performed focusing on the differentiation of PCa
from pancreatitis and normal tissue.14 15 The only clinically
available serum biomarker, CA19.9, is of limited use, cross-
sectional imaging techniques are unreliable and invasive endo-
scopic procedures are operator dependent and can give unclear
and false-positive ﬁndings.11 16 17 Thus, there is an urgent need
for the development of new and better diagnostic methods.11
13C magnetic resonance spectroscopic imaging (13C-MRSI)
using 13C-labelled substrates, in which the 13C nuclear spins
have been hyperpolarised using dynamic nuclear polarisation,
has revolutionised metabolic imaging with MR by increasing the
sensitivity of detection by >10 000-fold.18 This has allowed
imaging of hyperpolarised 13C labelled substrates and the meta-
bolites formed from them in vivo.19 Hyperpolarised [1-13C]
pyruvate has been the most widely used substrate, having shown
considerable promise in preclinical studies for tumour grading
and assessment of treatment response.19 20
We show here, in genetically engineered mouse models that
recapitulate many of the clinical, histopathological, genetic and
metabolic aspects of the human disease, that hyperpolarised
[1-13C]pyruvate has the potential to detect and follow the
progression of pancreatic precursor lesions towards invasive
PCa.21–24
MATERIALS AND METHODS
Animal preparation
Experiments complied with licences issued under the Animals
(Scientiﬁc Procedures) Act of 1986. Protocols were approved by
the Cancer Research UK, Cambridge Institute Animal Welfare
and Ethical Review Body. LSL-KrasG12D/+- p48Cre/+ (KC) mice
(2, 4 and 9 months old) with mPanIN lesions, LSL-KrasG12/D+;
LSL-Tpr53R172H/+;Pdx-1-Cre (KPC) mice (3–6 months old)
with spontaneous PCa, LSL-KrasG12D/+ and p48Cre/+ control
mice (age matched to KC mice), Pdx-1-Cre (PC) control mice
(age matched to KPC) and C57BL/6 control wild-type (wt)
mice, with no pancreatic lesions (6–8 weeks old) were used.23
Tumours were studied at <5 mm diameter. Acute pancreatitis
was induced in wt mice by six hourly intraperitoneal injections
with 50 μg/kg of caerulein (Sigma-Aldrich, Dorset, UK).25
Hyperpolarisation of [1-13C]pyruvate
[1-13C]Pyruvic acid samples (44 mg, 14 mol/L; 99% 13C) con-
taining 15 mmol/L of trityl radical, tris (8-carboxy-2,2,6,6-tetra-
(hydroxyethyl)-benzo-[1,2–4,5]-bis-(1,3)-dithiole-4-yl)-methyl
sodium salt (OX063; GE Healthcare, Amersham, UK) and
1.5 mmol/L of an aqueous solution of a gadolinium chelate
(Dotarem, Guerbet, Roissy, France) were polarised in a
Hypersense polariser (Oxford Instruments, Abingdon, UK). The
frozen sample was dissolved at 180°C in 6 mL buffer containing
40 mM HEPES, 94 mM NaOH, 30 mM NaCl and 50 mg/L
EDTA. Polarisation levels ranged from 16% to 25%, measured
using a polarimeter (Oxford Instruments, UK).
Magnetic resonance spectroscopy and imaging
Mice were anaesthetised by inhalation of 1–2% isoﬂurane
(Isoﬂo, Abbotts Laboratories, Maidenhead, UK) in air/O2
(75/25% vol/vol, 2 L/min). Body temperature was maintained
using warm air. Breathing rate (∼80 bpm) and body temperature
(37°C) were monitored (Biotrig, Small Animal Instruments,
Stony Brook, New York, USA). Experiments were performed in
a 7.0-T horizontal bore magnet (Agilent, Palo Alto, California,
USA) using an actively decoupled dual-tuned 13C/1H volume
transmit coil (Rapid Biomedical, Rimpar, Germany) and a 20
mm diameter 13C receiver coil (Rapid Biomedical). The pan-
creas was localised using respiratory-gated coronal and axial
T2-weighted fast spin-echo images (repetition time (TR) 2 s;
echo time (TE) 12 ms; ﬁeld of view (FOV) 80 mm×40 mm;
data matrix 512×256; slice thickness 1.25 mm; 12 slices).
Hyperpolarised [1-13C]pyruvate (0.3 mL, 82 mM) was injected
intravenously, via a tail vein catheter, over a period of 3 s, and
the animal placed inside the magnet. Axial 13C chemical-shift
images (CSI) (TR 30 ms; TE 1.5 ms; FOV 40×40 mm; data
matrix 32×32 with centre-out encoding order; spectral width
6 kHz; total acquisition time 30 s, ﬂip angle 5°) were collected
from the 4–8-mm-thick slices selected from the 1H images.
Spectroscopic image acquisition commenced 20±2 s after the
start of injection, with a total time between dissolution and data
acquisition of ∼30 s. CSI analysis was performed in MATLAB
(The Mathworks, Massachusetts, USA), by an independent
blinded observer. The data were multiplied by a cosine function
and zero-ﬁlled to 128 points in both spatial directions, line-
broadened to 20 Hz and zero-ﬁlled to 1024 points in the spec-
tral dimension before Fourier transformation, phase and base-
line correction and peak integration. A total of 139
spectroscopic imaging examinations were performed in 93 mice.
From these, 10 scans were excluded due to poor visualisation of
the pancreas (n=3), poor signal-to-noise ratio in the 13C spectra
(n=5) and death of the mouse following injection (n=2).
Measurements of enzyme activities and metabolite
concentrations
Mice were sacriﬁced by cervical dislocation and pancreatic tissue
rapidly excised and freeze-clamped using liquid nitrogen-cooled
tongs. Tissues were homogenised in radioimmunoprecipitation
assay buffer (50 mM HEPES, 1 mM EDTA, 0.7% sodium deoxy-
cholate, 1% Nonidet P-40, 0.5 M lithium chloride, pH 7.6),
using a Precellys 24 homogeniser (Stretton Scientiﬁc, Stretton,
UK). Homogenates were centrifuged and lactate dehydrogenase
(LDH) and alanine aminotransferase (ALT) (Abcam, Ref.
ab105134, Cambridge, UK) activities in the supernatant were
assayed spectrophotometrically.26 Lactate and alanine concentra-
tions were determined using 1H NMR spectroscopy. Tissues
were extracted using a methanol:chloroform:water protocol, and
high-resolution 1H and 1H-decoupled 13C NMR spectra were
obtained at 14.1 T (25°C, pH 7.2) using a Bruker 600 MHz
NMR spectrometer (Bruker, Ettlingen, Germany).27 The acquisi-
tion conditions were 1H, 90° pulses; 7.3 kHz spectral width;
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4.5 s acquisition time; 32k data points; 64 transients; and 12.5 s
recycling time; 13C, 30° pulses; 36.0 kHz spectral width; 0.9 s
acquisition time; 32k data points; 2048 transients; and 14 s
recycling time. Proton chemical shifts were referenced to 5 mM
3-(trimethylsilyl)-2,20,3,30-tetradeuteropropionic acid (TSP;
0.0 ppm), which was added to the samples. Peak integrals were
analysed using ACD/SpecManager (ACD/Labs, Bracknell, UK).
Data were zero-ﬁlled twice and multiplied by an exponential
function prior to Fourier transformation. All 1H NMR resonance
areas were normalised relative to the TSP resonance.
1H NMR measurements of 13C label exchange in pancreatic
tissue extracts
Freeze-clamped pancreatic tissue was homogenised (1:2; g/mL)
using a Precellys 24 homogeniser (Stretton Scientiﬁc, Stretton,
UK) in a buffer designed to simulate the intracellular conditions.
This contained 40 mM HEPES (pH 7.1) 10 mM nicotinamide,
2 mM dithiothreitol, 0.2 mM glutamate, 0.1 mM pyridoxal
phosphate, 0.4 mM NAD+ and 0.2 M KCl at 37°C. Unlabelled
alanine and lactate were added at concentrations equivalent to
those measured in the respective tissues (table 1). 13C label
incorporation from [3-13C]pyruvate into alanine and lactate
was measured using 1H NMR from the splitting of their respect-
ive methyl proton resonances due to 1H-13C coupling.
Measurements were made using a one-dimensional 1H-NOESY
sequence with continuous-wave solvent saturation of 3.7 s in a
total TR of 5.0 s with a mixing time of 0.15 s, 12.51 ppm spec-
tral width and 8192 complex points. The sample temperature
was maintained at 37°C. Spectra were analysed in MATLAB (The
Mathworks) and used to calculate the concentrations of
unlabelled and 3-13C labelled pyruvate, alanine and lactate at
each time point. Rates of isotope exchange between pyruvate and
alanine and lactate were calculated by ﬁtting a linear function to
the initial ﬁve points of the 3-13C alanine or lactate concentration
curves. These rate constants, corrected for the effect of dilution
of the tissue extract (wet weight (g) of homogenised tissue) in the
NMR tube sample volume (mL), were used to calculate the
extent of isotope exchange that would have been observed in
vivo at 20 s after injection of hyperpolarised [1-13C]pyruvate.
PET/CT
Clinical images were acquired 89 min after intravenous injection
of 356 MBq of 18F-labelled ﬂuorodeoxyglucose (18F-FDG).
Mice were fasted overnight prior to intravenous administration
of 5 MBq of 18F-FDG (IBA Molecular, Guildford, UK). Data
were acquired between 60 and 90 min in list-mode format on a
NanoPET/CT scanner (Mediso, Hungary). A CT image was
acquired for anatomic registration. PET images were recon-
structed using a two-dimensional ordered-subset expectation
maximisation method using ﬁve iterations and six subsets.
Images were normalised and corrected for decay, dead-time and
random events producing an image with 283 mm isotropic
voxels. The image was visualised using Vivoquant 1.23 software
(InviCRO, Massachusetts, USA).
Autoradiography
Autoradiography was performed following intravenous injection
of 10 MBq 18F-FDG 90 min prior to culling. The pancreas was
removed and snap-frozen in isopentane at −70°C before cryo-
sectioning (10 mm) at −18°C. Sections were thaw mounted,
dried and apposed overnight to a storage phosphor screen
before imaging on a Typhoon Trio (GE Healthcare) at 25 mm
resolution. Sections were then processed with H&E using stand-
ard methods.
Quantitative PCR
Pancreatic tissue samples were placed in a RNA later solution
(QIAGEN, Manchester, UK), stored for at least 24 h at 4°C and
then snap-frozen until processed. Total RNA was isolated using
the QIAGEN Tissue Lyser and QIAGEN RNeasy kits. cDNA
was synthesised from 1 μg of RNA using a QPCR cDNA
Synthesis Kit (Applied Biosystems, Paisley, UK) and analysed by
quantitative real-time PCR on a 7900 HT real-time PCR system
using relative quantiﬁcation (ΔΔCt) with the Taqman gene
expression assays (Applied Biosystems). FAM-labelled assays are
listed in online supplementary methods.
Histology and immunohistochemistry
Sections of formalin-ﬁxed parafﬁn-embedded tissue were stained
with H&E, anti-carbonic anhydrase IX (CAIX) rabbit poly-
clonal antibody (1:250 dilution) (Santa Cruz, sc-25600, Texas,
USA) and with anti-CD31 (1:50 dilution) rat monoclonal anti-
body (BD Biosciences, Ref. 553370, Oxford, UK). For quantiﬁ-
cation of mPanIN, pancreata were sectioned at 100 μm intervals
and individual mPanIN lesions were counted (ﬁgure 1).21
mPanIN lesions were classiﬁed as low grade (sum of mPanIN 1
and 1A) and high grade (sum of mPanIN 2 and 3), as described
previously.21 The Aperio Microvessel Analysis V.1 algorithm was
used to analyse CD31 staining (Leica Biosystems, Milton
Keynes, UK) and tuned to report longitudinal and transverse cut
vessels with a minimum vessel area threshold of 50 μm.
Statistical analysis and quantiﬁcation
Results are expressed as mean±SEM, unless stated otherwise.
Statistical signiﬁcance was tested using Prism V.6 (GraphPad
Software, San Diego, USA) with one-way analysis of variance
(ANOVA) (Tukey’s post hoc test) or Kruskal–Wallis test when
ANOVA assumptions were not met (Dunn’s post hoc test).
RESULTS
Glucose uptake in the mouse model and in humans
We used KPC mice that carry K-ras and p53 mutations, leading
to early onset of PDA, and KC mice, which have only the K-ras
mutation and which show slower progressing lesions and
develop PDA later in life.21 22 As in high-risk individuals, the
disease burden in the KC mice increased with time (ﬁgure 1),
with mice at 2 months having mainly normal tissue (∼60%) and
low-grade mPanIN (∼40%), at 4 months mainly low-grade
mPanIN and at 9 months equal amounts of low-grade and high-
grade mPanIN. Acute pancreatitis was induced in wt mice by
intraperitoneal injections of caerulein.25 Images and tissue
extracts for metabolite and enzymatic analysis were acquired
from the whole pancreas, and therefore, reﬂected the increasing
disease burden as the animals aged.
As in the human disease, PDA in these mice showed high
levels of 18FDG uptake in PET images, reﬂecting increased
glucose uptake and phosphorylation (ﬁgure 2). Autoradiography
of excised pancreas sections showed that increased FDG uptake
was conﬁned to regions containing mPanIN lesions and PDA
(ﬁgure 2). A recent study using an inducible KrasG12D model of
PDA demonstrated loss of FDG uptake and a decrease in
glucose uptake and lactate secretion following loss of KrasG12D
expression.28 This study also showed a decrease in expression of
the glucose transporter GLUT1 and in the hexokinases HK1
and HK2. Consistent with this previous study, we observed
increased expression of the glucose transporters GLUT1 and
GLUT3 and the hexokinases HK1 and HK2 in PDA compared
with normal tissue (ﬁgure 2).
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Changes in alanine and lactate concentrations and LDH and
ALT activities with disease progression
The alanine/lactate concentration ratio, measured in tissue
extracts, showed a signiﬁcant decrease with disease progression
(ﬁgures 3 and 4A), due primarily to an increase in lactate con-
centration, which was consistent with the increased FDG
uptake in mPanIN and PDA lesions (ﬁgure 2) and indicates an
increase in glycolytic ﬂux (table 1). There was also a progres-
sive increase in LDH activity (EC 1.1.1.27) (table 1). Decreases
in glucose uptake, lactate production and LDHA expression
have been reported previously following loss of KrasG12/D
expression in a similar mouse model of the disease.28 There
were no signiﬁcant changes in the mean vascular density
with disease progression (see online supplementary ﬁgure S1A),
indicating that these metabolic changes are unlikely to be
explained by changes in tissue perfusion. We also observed
very similar metabolic proﬁles in sarcomatoid and PDA
tumours (see ﬁgure 4), which have different morphology, with
sarcomatoid tumours being well-vascularised and stromal deﬁ-
cient. 29 There was, however, higher expression of CAIX in
high-grade lesions (see online supplementary ﬁgure S1B-D).30
There were no signiﬁcant differences in the concentration ratio
in the various mouse strains that do not develop disease (see
online supplementary ﬁgure S2 and table 2) nor in the activity
of LDH (table 2). There were also no signiﬁcant differences in
the alanine/lactate concentration ratios between the PDA
tumours that developed in KC mice and those that developed
in KPC mice (see online supplementary ﬁgure S2), demonstrat-
ing that the metabolic differences could not be attributed to
strain differences.
Table 1 Lactate and alanine concentrations and lactate dehydrogenase and alanine aminotransferase activities in tissue extracts
Tissue
Alanine concentration
(μmol/g of wet tissue)
Lactate concentration
(μmol/g of wet tissue)
Lactate dehydrogenase activity
(mU/mg of protein) (n=3)
Alanine aminotransferase activity
(mU/mg of protein) (n=3)
Control pancreas
(n=19)
1.82±0.32 1.55±0.24 204.35±53.1 6.10±0.35
Induced pancreatitis
(n=12)
1.19±0.2 1.36±0.20 300.78±93.0 9.09±1.25
4-month-old
pancreas (n=20)
0.98±0.11 1.80±0.20 616.44±100.05†(*) 5.09±1.32
9-month-old
pancreas (n=16)
1.08±0.30 4.24±1.21 763.46±106.40†(**) ‡(*) 3.94±0.23
Tumour
(sarcomatoid) (n=13)
4.58±1.00§(*) ¶(**) 17.80±4.1 §(***) †(****) ‡(****) 1008.9±49.25§(*) †(****) ‡(***) 0.28±0.01
Tumour (PDA)
(n=12)
1.70±0.37 8.14±1.67 §(**) †(***) ‡(**) 1142.44±19.55 §(**) ¶(*) †(****) ‡(****) 0.17±0.04‡(*)
Pancreatic tissues from controls (LSL-KrasG12D/+ (n=4); p48Cre (n=4); Pdx-1-Cre (PC) (n=6) and C57BL/6 wild-type (n=5)), 4-month-old and 9-month-old KC mice bearing mPanIN lesions
and KPC mice with tumours. Mean±SEM.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
†Significantly different compared with control pancreas.
‡Significantly different compared with induced pancreatitis.
§Significantly different compared with 4-month-old pancreas
¶Significantly different from 9-month-old pancreas.
KC, LSL-KrasG12D/+- p48Cre/+; KPC, LSL-KrasG12/D+;LSL-Tpr53R172H/+;Pdx-1-Cre; n, number of animals; PanIN, pancreatic intraepithelial neoplasia; PDA, pancreatic ductal adenocarcinoma.
Figure 1 Histological progression of
mPanIN in p48Cre;LSL-KrasG12D mice.
Percentage of normal (including % of
reactive ducts) and neoplastic ducts in
low-grade (sum of mPanIN 1 and 1A)
and high-grade (sum of mPanIN 2 and
3) lesions in mice with an average age
of 2 (n=6), 4 (n=4) and 9 months
(n=6).21 Mean±SEM; *p<0.05,
**p<0.01, ***p<0.001. n, number of
animals; PanIN, pancreatic
intraepithelial neoplasia.
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Imaging disease progression with hyperpolarised [1-13C]
pyruvate
13C CSI were acquired 20±2 s after intravenous injection of
hyperpolarised [1-13C]pyruvate from an axial 4–8-mm-thick
slice through the pancreas. Slice location was determined from
high-resolution T2-weighted
1H images (ﬁgure 5). We observed
signals from [1-13C]pyruvate, and from [1-13C]lactate
and [1-13C]alanine, which are formed by exchange of the
hyperpolarised 13C label between the injected pyruvate and
the endogenous lactate and alanine pools, respectively
(ﬁgure 6).31 32 The [1-13C]alanine/[1-13C]lactate signal ratio,
which had a coefﬁcient of variation of 20.9% (see online
supplementary table S1), showed the same decrease with
disease progression as the alanine/lactate concentration ratio
(ﬁgure 4B). With both measurements, tumour-bearing mice
and 9-month-old KC mice, which had a signiﬁcant amount of
high-grade mPanIN (ﬁgure 1), could be distinguished from
4-month-old KC mice and from control wt mice and wt mice
with induced pancreatitis. The capability of the technique to
distinguish between low-grade mPanIN and high-grade mPanIN
and tumour became even clearer when 2-month-old KC mice
were imaged as models of low-grade PanIN (ﬁgure 4B) as
these animals have very low levels of high-grade mPanIN
(ﬁgure 1).21 Similar but less marked trends were observed with
Figure 2 PET-CT images of pancreatic cancer in a human and in a LSL-KrasG12/D+;LSL-Tpr53R172H/+;Pdx-1-Cre (KPC) mouse and autoradiographic
analysis of 18F-ﬂuorodeoxyglucose (FDG) uptake in a 9-month-old control (wild-type (wt) mouse, and in a 13-month-old LSL-KrasG12D/+- p48Cre/+
(KC) mouse with mPanIN lesions and a pancreatic ductal adenocarcinoma (PDA) tumour and changes in hexokinase and glucose transporter
expression in PDA-containing pancreas compared with normal pancreas. Clinical images of a 70-year-old woman with metastatic adenocarcinoma of
the body of the pancreas and biopsy proven peritoneal and liver metastases. Coronal maximum intensity projection image (A) and axial (B)
18F-FDG-PET images acquired with time-of-ﬂight imaging at the level of the pancreas showing tracer uptake in the pancreatic tumour with a
maximum standardised uptake value (SUVmax) of 15.4. Axial contrast-enhanced CT (C) and fused PET-CT images (D) with the PET images shown as
a false-colour scale superimposed over the grey-scale CT images. Representative 18F-FDG PET-CT images from a KPC mouse (E) with histologically
conﬁrmed pancreatic ductal adenocarcinoma and a wt mouse (F). H&E staining of a representative normal pancreas (G) with corresponding 18F-FDG
autoradiography (H). H&E staining of a diseased pancreas from a KC mouse (I) and corresponding 18F-FDG autoradiography ( J). The signal
intensities in (H) and ( J) are comparable. Areas of distinct histopathology corresponding to the tissue sections in (I) and ( J) are shown in (N). At
high (20×) magniﬁcation, normal pancreatic tissue (L), splenic lymphoid tissue (spl.) (M), granuloma tissue (gran.) (O), pancreatic ductal
adenocarcinoma (P) and mouse pancreatic intraepithelial neoplasia14 are shown. Horizontal bars represent 100 mm. Overexpression of GLUT-1,
GLUT-3, hexokinase 1, hexokinase 2 and underexpression of glucokinase, GLUT-2, GLUT-4 and SGLT1 in PDA-containing pancreas (n=5) compared
with normal pancreas (n=4), measured by quantitative real-time-PCR (K). n, number of animals. PanIN, pancreatic intraepithelial neoplasia.
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disease progression in the [1-13C]alanine/[1-13C]pyruvate
and [1-13C]lactate/[1-13C]pyruvate signal ratios (see online
supplementary ﬁgure S3). The corresponding inverse trends
were observed in the lactate/alanine concentration and [1-13C]
lactate/[1-13C]alanine signal ratios (see online supplementary
ﬁgure S3). There were no signiﬁcant differences in the
Figure 3 13C and 1H MR spectra
acquired at different stages of disease
progression. The predominant lesion
present is indicated in the tissue
sections obtained post mortem. The 1H
spectra were acquired from pancreatic
tissue extracts and the 13C spectra
were acquired in vivo following
injection of hyperpolarised [1-13C]
pyruvate. In each condition, alanine
and lactate resonances are plotted on
the same scale, normalised to the
alanine integral in the 1H spectra and
to the pyruvate peak in the 13C
spectra. Ala, alanine; Lac, lactate; Pyr,
pyruvate; Pyr H, pyruvate hydrate.
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hyperpolarised [1-13C]alanine/[1-13C]lactate signal ratios in those
strains that do not develop disease (see online supplementary
ﬁgure S2).
In order to determine whether disease progression could be
followed in the same individual, we imaged KC mice (n=16),
and a cohort of control littermates (n=7), at 2, 4 and 9 months
of age. Disease progression was conﬁrmed in another group of
KC mice (n=16) where pancreas histology was assessed by an
independent blinded observer (ﬁgure 1). The higher percentage
of high-grade lesions found in the 4-month-old and
9-month-old KC mice, compared with that observed previously,
may be explained by the different promoter (p48) used here to
drive Cre recombinase expression.21 Imaging of these animals,
following injection of hyperpolarised [1-13C]pyruvate, showed
that there was a 44% and a 71% decrease in the [1-13C]alanine/
[1-13C]lactate signal ratio between 2-month-old and 4-month-old
Figure 4 Alanine/lactate concentration ratios measured by 1H NMR in pancreatic tissue extracts (A) and the corresponding hyperpolarised [1-13C]
alanine/[1-13C]lactate signal ratios observed in 13C chemical shift images of the pancreas (B) of control mice between 2 and 9 months; KC mice at 2,
4 and 9 months and tumour-bearing KPC mice. Changes in the [1-13C]alanine/[1-13C]lactate signal ratios in individual KC (n=16) (C) and control
mice (n=7) (D) at the indicated ages. Mean±SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. n, number of animals. PDA, pancreatic ductal
adenocarcinoma.
Table 2 Lactate and alanine concentrations and lactate dehydrogenase activities measured in the pancreas of the different mouse strains used
in this study that do not develop disease
Tissues
Alanine
(μmol/g of wet tissue)
Lactate
(μmol/g of wet tissue)
Lactate dehydrogenase activity
(mU/mg of protein) (n=3)
Wt (C57BL/6) (n=5) 3.81±0.46† (*) 3.00±0.31† (*) 204.35±53.10
p48Cre/+ (n=4) 1.30±0.42 1.07±0.34 369.6±80.2
LSL-KrasG12D/+ (n=4) 1.16±0.28 1.12±0.26 229.88±20.50
Pdx-1-Cre (PC) (n=6) 0.93±0.06 0.95±0.13 222.54±55.93
Mean±SEM.
*p<0.05.
†Significantly higher compared with PC.
n, number of animals; wt, wild-type.
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and 9-month-old mice, respectively, as well as a 50% decrease
between 4-month-old and 9-month-old KC mice (ﬁgure 4C),
which was consistent with the measurements on groups of
animals (ﬁgure 4B). Control littermates (LSL-KrasG12D/+; p48Cre;
Pdx-1-Cre (PC) and C57BL/6 wt) showed either no change in
the ratio or an increase (ﬁgure 4D).
Measurements of 13C labelling in pancreas extracts
Imaging of lactate and alanine labelling in the pancreas in vivo
was validated by measuring 13C labelling of alanine and lactate
in rapidly excised and freeze-clamped pancreas and by measur-
ing label exchange in cell-free pancreas homogenates.
Partitioning of 13C label between injected, non-hyperpolarised,
Figure 5 Identiﬁcation and
anatomical location of the pancreas in
a wild-type (wt) mouse (A), a
9-month-old LSL-KrasG12D/+- p48Cre/+
(KC) mouse (B), a LSL-KrasG12/D+;
LSL-Tpr53R172H/+;Pdx-1-Cre (KPC)
mouse with a pancreatic ductal
adenocarcinoma tumour (C) and a
4-month-old KC mouse (D), in axial
(A and C) and coronal (B and D)
T2-weighted
1H images and at
necropsy. Necropsy of the wt mouse
(E) from which the image shown in (A)
was acquired and the corresponding
necropsy (F) and histology (G) of the
4-month-old KC mouse from which the
image shown in (D) was acquired.
Consistent attachment of the pancreas
to the spleen was identiﬁed by MRI
and at necropsy. The pancreas, or
tumour in the case of (C), are
demarcated by a white line. Open
arrows indicate normal and diseased
pancreas and tumour; white ﬁlled
arrows indicate spleen; white circles
indicate liver; black arrows indicate
areas of normal pancreas and black
circles indicate examples of areas of
low-grade mPanIN.
Figure 6 Representative 13C spectroscopic images showing the spatial distribution of labelled pyruvate, lactate and alanine in control (wild-type
(wt)), 4-month-old and 9-month-old LSL-KrasG12D/+- p48Cre/+ (KC) mice. The lactate, alanine and the alanine/lactate ratio are displayed as voxel
intensities relative to the maximal pyruvate signal. In the case of alanine and lactate, these have been increased by a factor of 3 to aid visualisation.
The [1-13C]alanine/[1-13C]lactate signal ratio is shown for a region of interest that encompasses the pancreas. The location of the pancreas was
identiﬁed in the T2-weighted
1H images, which are shown in grey scale. The pancreas is outlined in white on the anatomical image. A ﬁducial
marker was included to serve as a reference. The colour scales represent arbitrary linearly distributed intensities for the hyperpolarised images.
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[3-13C]pyruvate, and endogenous alanine and lactate was repro-
duced in cell-free pancreatic tissue extracts, where the decrease
in the [3-13C]-labelled alanine/lactate signal ratio with disease
progression was similar to that measured in freeze-clamped
tissue extracts prepared 20 s after intravenous injection of
[3-13C]pyruvate (table 3) and similar also to the hyperpolarised
[1-13C]alanine/[1-13C]lactate ratio measured in vivo in
9-month-old KC and tumour-bearing mice (ﬁgure 4B). The
lower ratio observed in vivo for normal tissue, pancreatitis and,
to a lesser extent, for 4-month-old mice may reﬂect partial
volume effects, where tissue outside the pancreas was imaged.
DISCUSSION
We have shown that imaging exchange of hyperpolarised 13C
label between injected [1-13C]pyruvate and the endogenous
alanine and lactate pools can be used to detect and follow the
progression of pancreatic precursor lesions, differentiating
normal pancreas, pancreatitis and tissue with predominantly
low-grade mPanIN from tissue with predominantly high-grade
mPanIN and tumour. This distinction is the most important clin-
ically since patients with high-grade lesions or early-stage PCa
could be offered potentially curative surgery.11 Differentiation
was most clear for KC mice at 2 months of age, where there was
largely normal tissue and low-grade mPanIN present (ﬁgure 1),
in which was no overlap of the hyperpolarised [1-13C]alanine/
[1-13C]lactate signal ratios with the ratios observed in
9-month-old and tumour-bearing animals (ﬁgure 4B). However,
although we could distinguish in these inbred mouse strains pan-
creas with predominantly low-grade mPanIN from tissue with
predominantly high-grade mPanIN and tumour, it is unlikely
that these thresholds for the 13C-labelled alanine/lactate ratio
would be preserved or indeed consistent in an outbred human
population. Instead, we envisage that the technique would be
used in human individuals at high risk of developing PCa to
look for evidence of the presence of disease and subsequently to
monitor disease progression. The feasibility of such an approach
was demonstrated by following disease progression in individual
animals (ﬁgure 4C).
The decrease in the [1-13C]alanine/[1-13C]lactate signal ratio
can be explained by increases in lactate concentration (ﬁgure 3)
and LDH activity and a decrease in ALT activity (EC 2.6.1.2)
(table 1).19 31 Alanine concentration also affects 13C hyperpo-
larised label exchange between [1-13C]pyruvate and alanine
(see online supplementary table S2); however, the alanine con-
centrations were largely unchanged (table 1). Increased LDH
activity has been reported in human PCa and decreases in
glucose uptake and lactate production and in GLUT1, HK1,
HK2 and LDHA expression have been reported previously fol-
lowing loss of KrasG12/D expression in a similar mouse model of
PCa.28 33 Although we observed an increase in CAIX expres-
sion, which is regulated by HIF1α, HIF1α is not thought to
play a signiﬁcant role in glycolytic enzyme expression in this
model of PCa.28 30 Instead, the MAPK pathway and
Myc-directed transcription are thought to play key roles.28
Similar patterns of lactate and alanine labelling, following injec-
tion of hyperpolarised [1-13C]pyruvate, have been observed
previously in prostate tumours, where increased lactate labelling
was observed with increasing histological grade and in a
c-Myc-driven liver cancer model, where higher alanine labelling
was observed in pre-cancerous lesions and higher lactate label-
ling in the resulting tumours.20 34
Several promising molecular imaging probes for detection of
PanIN lesions have been described, including Claudin-4 and
cathepsin-activatable near-infrared probes and a single-photon
emission CT (SPECT) probe, based on Plectin-1, which detected
primary pancreatic tumours and metastatic foci in orthotopic
mouse models of PDA.35–37 The 13C-MRSI experiment
described here, however, has several potential advantages. In
contrast to imaging with NIR probes, which may be limited by a
requirement to use invasive and operator-dependent procedures,
such as endoscopy or laparotomy, the technique could be used
to produce non-invasive three-dimensional metabolic maps of
the pancreas, at depth, which should allow more ready detec-
tion of diseased areas. Unlike imaging with PET or SPECT
probes, the technique does not use ionising radiation and there-
fore could be used to screen and follow-up high-risk patients
over a prolonged period of time.37 Recent observations suggest
that at least 10 years are needed for the initiating mutation to
evolve into invasive carcinoma within the high-grade PanIN
lesion and an additional 5–6 years are required before cancer
cells acquire metastatic capability.38 The technique may also
offer opportunities for ultrasound (US)-guided targeted endo-
scopic biopsies using fused US-MRSI images.
A limitation of the current study was the extent of disease in
the mouse model, where in 9-month-old KC mice high-grade
mPanIN occupied ∼40% of the pancreas. However, the human
pancreas is considerably larger, measuring approximately 12–20
cm×2 cm×2 cm as compared to ∼1.8 cm×∼5 mm (craniocau-
dal axis)×∼3 mm (anteroposterior axis) in the mouse, and in
individuals with FPC PanIN lesions consist of small, generally
<5 mm, intraductal lesions, which in high-risk individuals are
focally distributed at a rate of 1.51 lesions/cm2.39–43 Since the
voxel size used in the ﬁrst clinical study in prostate cancer was
7×7×7 mm3, which it may be possible to improve on with
Table 3 Partition of 13C label between alanine and lactate following incubation of [3-13C]pyruvate with pancreatic tissue homogenates and in
pancreatic tissues in vivo following intravenous injection of [3-13C]pyruvate
Pancreatic tissue type
Concentrations of added metabolites
[3-13C]alanine/[3-13C]lactate ratio
in pancreatic homogenates
13C-alanine/13C-lactate ratio in vivo
(20 s after intravenous injection of
[3-13C]pyruvate)Alanine (mM) Lactate (mM)
Control 2 2 3.34 2.28
Induced pancreatitis 1 1 1.33 0.56
4-month-old mice 1 2 0.85 0.62
9-month-old mice 1 4 0.11 0.17
Tumour (PDA) 2 9 0.04 0.09
Partitioning of the 13C label between alanine and lactate was measured in pancreatic tissue homogenates using dynamic 1H NMR measurements and by 13C NMR in pancreatic tissue
that was rapidly excised 20 s after intravenous injection of 0.3 mL of 82 mM [3-13C]pyruvate.
PDA, pancreatic ductal adenocarcinoma.
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higher levels of polarisation, then we believe that both the
image resolution and the disease burden should be sufﬁcient to
detect disease progression in the clinic.44 45 The main factor
limiting translation to the clinic is the short half-life of the
hyperpolarised 13C label. Nevertheless, initial results from the
ﬁrst clinical trial have shown this to be sufﬁcient to probe
lesions in the prostate.44
The absolute signal intensities from pyruvate, alanine and
lactate are dependent on a number of factors, including the
degree of polarisation of the injected pyruvate, transit time,
amount of pyruvate delivered to the tissue and the variable rate
of loss of polarisation in all three species. However, by measuring
the ratio of the signal in alanine and lactate, which depends
mainly on the relative activities of LDH and ALTand the alanine
and lactate pool sizes, these factors are largely corrected for.
In summary, improved diagnostic tools for screening and
follow-up of individuals at high risk of developing PCa repre-
sent a clear and unmet clinical need.11–13 We have shown here
that imaging exchange of hyperpolarised 13C label between
injected [1-13C]pyruvate and the endogenous alanine and lactate
pools, in well-established and realistic mouse models of the
disease, can be used to non-invasively detect and follow progres-
sion of pancreatic preneoplastic lesions. The technique may
provide an improved diagnostic and screening tool for indivi-
duals at high risk of developing PCa, enabling not only a better
risk stratiﬁcation but also earlier curative intervention with
potential improvements in overall prognosis and patient sur-
vival. However, the true potential of the technique can only be
established in clinical studies on patients with PCa and on indi-
viduals at risk of developing the disease.
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